Hepatocyte-like cells (HLCs) derived from human pluripotent stem cells are a promising cell source for drug screening and toxicity tests. Thus, various hepatic differentiating protocols have been developed, leading to a hepatic differentiation efficiency of approximately 90%. However, HLC drug metabolizing ability remains very low compared to human primary hepatocytes. In order to overcome this problem, several alternative methods, such as, co-culture, three-dimensional (3D) culture, bioreactor, nanochip-based, etc., have been developed, but optimization to produce fully functional HLCs is ongoing. Recently, our group reported that repeated exposure of HLCs to xenobiotics can improve the expression of hepatic metabolizing enzymes such as cytochrome P450s (CYPs) and glutathione S-transferases (GSTs). These data suggest that we should develop strategies for differentiating cells into mature HLCs by more closely mimicking in vivo fetal and postnatal liver development. Here, we review the current development of alternative methods for enhancing the drug metabolizing functions of HLCs derived from human embryonic stem cells, humaninduced pluripotent stem cells, and mesenchymal stem cells as used for drug screening and toxicity tests. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Clinical treatment for chronic liver failure using human embryonic stem cell (hESC) and human-induced pluripotent stem cell (hiPSC)-derived hepatocyte-like cells (HLCs) is considered a promising alternative method to organ transplantation. In addition to their use for treatment in liver failure, stem cell-derived HLCs have been considered for in vitro drug screening and toxicology researches [1] . Therefore, HLCs directly induced from hESCs have been intensively studied, resulting in a significant improvement in the efficiency of hepatic differentiation using human pluripotent stem cells. Albumin-positive HLCs can now be produced at the end of in vitro hepatic differentiation at levels up to 90% [2, 3] . However, in spite of efforts to induce further maturation of HLCs derived from human pluripotent stem cells, the phenotype of most HLCs is more similar to fetal hepatocytes rather than fully mature hepatocytes. Critical inducing mature hepatocyte functions, such as phase I and II enzyme activity, tend to be significantly reduced in 2D-cultured HLCs (approximately <1% of human primary hepatocytes) [4, 5] . Furthermore, under in vitro culture conditions, hepatobiliary transporter expression rapidly decreases [6] , and most HLCs are spontaneously differentiate into various cell lineages, regardless of the differentiation protocol. Thus, at the final stage of hepatic differentiation, purification is needed to obtain highly homogenous HLCs. These key differences between HLCs and human primary hepatocytes result in limited use of HLCs as A lack of knowledge regarding the developmental signaling pathways that control in vivo hepatic maturation contributes to the development of immature HLCs, which usually display a fetal phenotype. Therefore, in this review paper, we will discuss current hepatic differentiation culture systems that enhance hepatic maturation of HLCs and gain a metabolizing response against xenobiotics at a level similar to that of human primary hepatocytes.
ALTERNATIVE CULTURE SYSTEMS TO ENHANCE HEPATIC FUNCTIONS

Co-culture system
During organogenesis, differentiation of pluripotent cells into functional hepatocytes is controlled by a complex signaling pathway of molecular events. Therefore, the most direct way of inducing hepatic differentiation is to mimic the in vivo signaling pathway present during liver development. Studies have clearly defined many of these molecular events, such as reduced Oct4 activity, which allows for the activation of FoxA2 (HNF3β), SOX17, and GATA4, a process necessary for the differentiation of endodermal cells into hepatocytes [7] . Fair et al. reported that murine ESCs in co-culture with chick cardiac mesodermal cells were successfully differentiated into early hepatocyte lineage as determined by morphology and induction of HNF3β, SOX17, and GATA4 genes [7] .
Furthermore, cardiac mesodermal cells can be stimulated to form hepatic progenitor colonies in vitro. Cardiac mesoderm cells are used for hepatic differentiation because their fibroblast growth factor (FGF 1 and 2) induces competent foregut endodermal cells, which are further differentiated into hepatocytes [7] . As our knowledge of liver development during organogenesis increases, more developmentally correlated co-culture systems can be established for hepatic maturation of HLCs. [10] .
A recent study reported that a combination of cell-cell interaction using micro-patterned dishes and co-culture with murine embryonic fibroblasts significantly increased gene expression and activity of hepatic drug metabolizing enzymes (Phase I and II) in HLCs as well as long-term culture (a month) [11] .
Disadvantages of a co-culture system are the presence of difficult-to-define inducing factors as well as the need for another cell source for hepatic maturation of HLCs. Additionally, at the final stage of hepatic differentiation, a purification procedure is required to discard co-cultured cells and to harvest homogenous HLCs.
3D culture system
Organogenesis takes place in a 3D manner, with cell-cell interaction occurring on an ECM structure rather than a 2D flat sheet [12] . Table 1 summarizes recent studies that report on either gene expression or activity of hepatic metabolizing enzymes of human pluripotent stem cell-derived HLCs using a 2D or 3D culture system. Interestingly, a few studies measure both protein levels of metabolizing enzymes and activity of induced enzymes.
Various 3D culture systems have been developed for hepatic differentiation such as ultra-low attached dish, microsound bottom well plate, porous scaffold, nanopattern chip, droplet culture, and ECM.
Our group reported on HLC culturing using 3D embryonic body (EB) and 3D cultured definitive endodermal spheroid formation with lithium chloride [40, 41] . However, it was difficult to prevent spontaneous differentiation during EB-or 3D culturd hepatic spheroid-mediated induction. Therefore, a purification procedure at the final stage of hepatic differentiation was needed to obtain homogenous HLCs. Most importantly, the expression of a typical hepatic cytochrome P450 (CYP)3A4 was still low, and its activity was increased -1.5 times by acetaminophen treatment. Recently, we successfully optimized our protocol and our > 90% of albumin-positive HLCs were produced (Fig. 1) . However, expression and activity of hepatic metabolizing enzymes in 2D cultured
HLCs were much more improved but still not reached the levels of human primary hepatocytes. Therefore, we further enhanced the hepatic metabolizing ability of HLCs using a 3D culture system and repeated exposure to xenobiotics (Fig. 2,3 ) [8] .
A disadvantage of using a 3D culture system is that HLCs, which are at the core of 3D cell clumps or spheroids, can easily undergo apoptosis due to hypoxic conditions and lack of nutrient penetration. Apoptosis of HLCs in a 3D spheroid of approximately >300 μm in diameter begins to increase. Therefore, it is important to optimize the homogenous size of 3D hepatic spheroids.
Bioreactor
Bioreactor refers to a manufactured or engineered device pro- 
COMMERCIALLY AVAILABLE FUNCTIONAL HLCS
There are several commercially available HLCs derived from human pluripotent stem cells. Table 2 summarizes the major providers, cell types, characteristics, and servicing assays of these available HLCs [4, [45] [46] [47] [48] [49] . An important factor for producing commer- Note that the HLCs and hepatic spheroids derived from BGO1 hESCs were exposed to each xenobiotic concentration at the end of stage III. The xenobiotic treatment was then withdrawn for 2 days followed by a second exposure for 2 days. (B) qPCR analysis of ALB and three transcription factors known for their expression in mature hepatocytes (PROX1, C/EBPa, and ATF5) and phase I enzymes (CYP1A2, CYP2D6, CYP2C9, CYP3A4, and CYP3A7) in 2D-cultured HLCs after repeated exposure to xenobiotics. The 'a' denotes statistical significance. Control (C, untreated HLCs); the 'b' denotes statistical significance, compared to the first exposure of its own group. Phenobarbital (PB, widely prescribed as an anti-seizure medication in children); Acetaminophen (AP, a common cold medication); rifampicin (RIF, an antibiotic used to treat infections ® hepatocytes have been genotyped for 1,936 ADME markers in over 200 genes, including all FDA-validated genes and > 90% of the ADME Core markers as defined by the PharmaADME group ( Fig. 1 ) [8] . It was the first report to demonstrate that HLCs can be "educated," suggesting that they can acquire a "learned" response to hepatotoxins.
FUTURE CHALLENGES AND SUGGESTIONS
Our strategy is based on the idea that hepatic metabolizing ability (activity of Phase I and II) has been primarily accomplished within the first three years of life. A neonate's liver has only -20% of the hepatocytes that will be present in the adult hepatocytes [54] . Therefore, the metabolizing rate and function of neonatal hepatocytes against to xenobiotics are low. 
CONCLUSION
The main concern in hepatic differentiation using human plu- 
